Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (106)

« Back to Publications

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma.

Fuentes-Lacouture M-C. et al, (2026), FEBS J

Early plasma proteomic alterations precede amyloidosis diagnosis, reflecting cardiac and immune dysregulation

Hasheminasab SA. et al, (2026)

Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma.

Bjorklund CC. et al, (2026), Blood Neoplasia, 3

Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis.

Fieggen J. et al, (2025), Blood Adv, 9, 3766 - 3770

Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis

Riva SG. et al, (2024), Blood, 144, 2525 - 2525

KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Simoglou Karali C. et al, (2024), Blood, 144, 2527 - 2527

Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.

Van Oekelen O. et al, (2024), Cell Rep Med, 5

Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.

Amatangelo M. et al, (2024), Cell Rep Med, 5

Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.

Jeyaraju DV. et al, (2024), Haematologica, 109, 1082 - 1094

Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.

Garbowski MW. et al, (2024), Am J Hematol, 99, 182 - 192

ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.

Neri P. et al, (2024), Blood Cancer Discov, 5, 56 - 73

Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Gooding S. et al, (2024), BLOOD, 144, 3333 - 3334

Multiple myeloma and its treatment contribute to increased platelet reactivity.

Mitchell JL. et al, (2023), Platelets, 34

Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients

Agarwal G. et al, (2023), Blood, 142, 644 - 644

Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.

Menezes DL. et al, (2023), Br J Haematol, 201, 1129 - 1143

Load More

1
2
3
4
5
6
7
...
»